Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients
Summary Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients. Introduction The ai...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2014-12, Vol.25 (12), p.2755-2765 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2765 |
|---|---|
| container_issue | 12 |
| container_start_page | 2755 |
| container_title | Osteoporosis international |
| container_volume | 25 |
| creator | Ebina, K. Hashimoto, J. Shi, K. Kashii, M. Hirao, M. Yoshikawa, H. |
| description | Summary
Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients.
Introduction
The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
Methods
The effects of TPTD were examined between RA (
n
= 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (
n
= 62; age 71.3 years) with 77.4 % of prior BP.
Results
Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %,
P
= 0.038), whereas it was 9.7 versus 7.9 % (
P
= 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (
β
= 0.446,
P
= 0.005) and baseline ucOC for FN (
β
= 0.554,
P
= 0.001), in which both showed significant negative correlation with baseline PSL dose.
Conclusions
RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis. |
| doi_str_mv | 10.1007/s00198-014-2819-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1627963708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3483189501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-91c813cb044a90dc29f19cd64e388487b4130281905c4ef3a766fba6a3dcf243</originalsourceid><addsrcrecordid>eNqNkU1rFTEYhYMo9rb6A9xIwI2baL4mmSzlUrVQcNOFu5CbD2_KTDImGWx_iP_XDLcVEQRXycv7nBNODgCvCH5HMJbvK8ZEjQgTjuhIFLp7AnaEM4aoEsNTsMOKSaQ4-XoGzmu9xV2jlHwOzuiARzoMYgd-7vO8mBJrTjAH2I4e-hC8bdtERjTn1I7QmTjdw-ZL7Kxp0Xlo3BxTrG0bN22CS7_51Cr8EbukHP06m5ajg6a0Y4ktVmiSg0uubfYpL2atZoJ98nnJJde-f7R4AZ4FM1X_8uG8ADcfL2_2n9H1l09X-w_XyHI5NKSIHQmzB8y5UdhZqgJR1gnu2TjyUR44YXj7GTxY7gMzUohwMMIwZwPl7AK8PdkuJX9ffW16jtX6aTLJ57VqIqhUgkk8_g9KsSBKyI6--Qu9zWtJPcdG4YH3vjZDcqJsj16LD3opcTblXhOst3b1qV3dab1l0Hdd8_rBeT3M3v1WPNbZAXoCal-lb7788fQ_XX8BTMazLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1620540148</pqid></control><display><type>article</type><title>Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ebina, K. ; Hashimoto, J. ; Shi, K. ; Kashii, M. ; Hirao, M. ; Yoshikawa, H.</creator><creatorcontrib>Ebina, K. ; Hashimoto, J. ; Shi, K. ; Kashii, M. ; Hirao, M. ; Yoshikawa, H.</creatorcontrib><description>Summary
Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients.
Introduction
The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
Methods
The effects of TPTD were examined between RA (
n
= 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (
n
= 62; age 71.3 years) with 77.4 % of prior BP.
Results
Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %,
P
= 0.038), whereas it was 9.7 versus 7.9 % (
P
= 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (
β
= 0.446,
P
= 0.005) and baseline ucOC for FN (
β
= 0.554,
P
= 0.001), in which both showed significant negative correlation with baseline PSL dose.
Conclusions
RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-014-2819-x</identifier><identifier>PMID: 25082556</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Absorptiometry, Photon - methods ; Aged ; Aged, 80 and over ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - physiopathology ; Biomarkers - blood ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - therapeutic use ; Bone Remodeling - drug effects ; Drug Administration Schedule ; Endocrinology ; Female ; Femur Neck - physiopathology ; Hip Joint - physiopathology ; Humans ; Lumbar Vertebrae - physiopathology ; Male ; Medicine ; Medicine & Public Health ; Menopause ; Middle Aged ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - physiopathology ; Prospective Studies ; Rheumatoid arthritis ; Rheumatology ; Steroids ; Teriparatide - administration & dosage ; Teriparatide - therapeutic use</subject><ispartof>Osteoporosis international, 2014-12, Vol.25 (12), p.2755-2765</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-91c813cb044a90dc29f19cd64e388487b4130281905c4ef3a766fba6a3dcf243</citedby><cites>FETCH-LOGICAL-c475t-91c813cb044a90dc29f19cd64e388487b4130281905c4ef3a766fba6a3dcf243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-014-2819-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-014-2819-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25082556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebina, K.</creatorcontrib><creatorcontrib>Hashimoto, J.</creatorcontrib><creatorcontrib>Shi, K.</creatorcontrib><creatorcontrib>Kashii, M.</creatorcontrib><creatorcontrib>Hirao, M.</creatorcontrib><creatorcontrib>Yoshikawa, H.</creatorcontrib><title>Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients.
Introduction
The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
Methods
The effects of TPTD were examined between RA (
n
= 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (
n
= 62; age 71.3 years) with 77.4 % of prior BP.
Results
Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %,
P
= 0.038), whereas it was 9.7 versus 7.9 % (
P
= 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (
β
= 0.446,
P
= 0.005) and baseline ucOC for FN (
β
= 0.554,
P
= 0.001), in which both showed significant negative correlation with baseline PSL dose.
Conclusions
RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.</description><subject>Absorptiometry, Photon - methods</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Biomarkers - blood</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone Remodeling - drug effects</subject><subject>Drug Administration Schedule</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Femur Neck - physiopathology</subject><subject>Hip Joint - physiopathology</subject><subject>Humans</subject><subject>Lumbar Vertebrae - physiopathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - physiopathology</subject><subject>Prospective Studies</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Steroids</subject><subject>Teriparatide - administration & dosage</subject><subject>Teriparatide - therapeutic use</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkU1rFTEYhYMo9rb6A9xIwI2baL4mmSzlUrVQcNOFu5CbD2_KTDImGWx_iP_XDLcVEQRXycv7nBNODgCvCH5HMJbvK8ZEjQgTjuhIFLp7AnaEM4aoEsNTsMOKSaQ4-XoGzmu9xV2jlHwOzuiARzoMYgd-7vO8mBJrTjAH2I4e-hC8bdtERjTn1I7QmTjdw-ZL7Kxp0Xlo3BxTrG0bN22CS7_51Cr8EbukHP06m5ajg6a0Y4ktVmiSg0uubfYpL2atZoJ98nnJJde-f7R4AZ4FM1X_8uG8ADcfL2_2n9H1l09X-w_XyHI5NKSIHQmzB8y5UdhZqgJR1gnu2TjyUR44YXj7GTxY7gMzUohwMMIwZwPl7AK8PdkuJX9ffW16jtX6aTLJ57VqIqhUgkk8_g9KsSBKyI6--Qu9zWtJPcdG4YH3vjZDcqJsj16LD3opcTblXhOst3b1qV3dab1l0Hdd8_rBeT3M3v1WPNbZAXoCal-lb7788fQ_XX8BTMazLw</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Ebina, K.</creator><creator>Hashimoto, J.</creator><creator>Shi, K.</creator><creator>Kashii, M.</creator><creator>Hirao, M.</creator><creator>Yoshikawa, H.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20141201</creationdate><title>Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients</title><author>Ebina, K. ; Hashimoto, J. ; Shi, K. ; Kashii, M. ; Hirao, M. ; Yoshikawa, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-91c813cb044a90dc29f19cd64e388487b4130281905c4ef3a766fba6a3dcf243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Absorptiometry, Photon - methods</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Biomarkers - blood</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone Remodeling - drug effects</topic><topic>Drug Administration Schedule</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Femur Neck - physiopathology</topic><topic>Hip Joint - physiopathology</topic><topic>Humans</topic><topic>Lumbar Vertebrae - physiopathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - physiopathology</topic><topic>Prospective Studies</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Steroids</topic><topic>Teriparatide - administration & dosage</topic><topic>Teriparatide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebina, K.</creatorcontrib><creatorcontrib>Hashimoto, J.</creatorcontrib><creatorcontrib>Shi, K.</creatorcontrib><creatorcontrib>Kashii, M.</creatorcontrib><creatorcontrib>Hirao, M.</creatorcontrib><creatorcontrib>Yoshikawa, H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebina, K.</au><au>Hashimoto, J.</au><au>Shi, K.</au><au>Kashii, M.</au><au>Hirao, M.</au><au>Yoshikawa, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>25</volume><issue>12</issue><spage>2755</spage><epage>2765</epage><pages>2755-2765</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients.
Introduction
The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
Methods
The effects of TPTD were examined between RA (
n
= 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (
n
= 62; age 71.3 years) with 77.4 % of prior BP.
Results
Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %,
P
= 0.038), whereas it was 9.7 versus 7.9 % (
P
= 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (
β
= 0.446,
P
= 0.005) and baseline ucOC for FN (
β
= 0.554,
P
= 0.001), in which both showed significant negative correlation with baseline PSL dose.
Conclusions
RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.</abstract><cop>London</cop><pub>Springer London</pub><pmid>25082556</pmid><doi>10.1007/s00198-014-2819-x</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2014-12, Vol.25 (12), p.2755-2765 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1627963708 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Absorptiometry, Photon - methods Aged Aged, 80 and over Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - physiopathology Biomarkers - blood Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - therapeutic use Bone Remodeling - drug effects Drug Administration Schedule Endocrinology Female Femur Neck - physiopathology Hip Joint - physiopathology Humans Lumbar Vertebrae - physiopathology Male Medicine Medicine & Public Health Menopause Middle Aged Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Prospective Studies Rheumatoid arthritis Rheumatology Steroids Teriparatide - administration & dosage Teriparatide - therapeutic use |
| title | Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A08%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20effect%20of%2018-month%20daily%20teriparatide%20administration%20on%20patients%20with%20rheumatoid%20arthritis%20and%20postmenopausal%20osteoporosis%20patients&rft.jtitle=Osteoporosis%20international&rft.au=Ebina,%20K.&rft.date=2014-12-01&rft.volume=25&rft.issue=12&rft.spage=2755&rft.epage=2765&rft.pages=2755-2765&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-014-2819-x&rft_dat=%3Cproquest_cross%3E3483189501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1620540148&rft_id=info:pmid/25082556&rfr_iscdi=true |